A workplace breast cancer screening program: Costs and components

Peggy Schrammel, Robert I. Griffiths, Claudia B. Griffiths

Research output: Contribution to journalArticle

Abstract

Screening for breast cancer can result in early detection of malignancies and lives saved. Many employers now offer periodic screening as an employee health benefit, and some have established screening programs in the workplace. This study was performed to identify the employer costs of breast cancer screening in the workplace, referrals for suspicious findings, and initial treatment of malignant disease. Additionally, the costs for these same services, had they been obtained outside of a workplace screening program, were estimated. Data on program components and associated costs for an established employer based breast cancer screening program were obtained. These costs were compared to those among a hypothetical cohort of women not enrolled in the workplace screening program. From 1989 through 1995, 1,416 women participated in the program. Nearly 2,500 screening mammograms and approximately 2,773 clinical breast examinations were performed, resulting in 292 referrals to physicians outside of the program for additional diagnostic procedures and treatment as needed. These referrals resulted in the detection of 12 malignancies: 8 Stage I; 3 Stage II; and 1 Stage III. Mammographic and clinical breast examination screening cost $249,041; referrals resulting in benign disease or no detectable disease cost $185,002; and referrals resulting in malignant disease, followed by initial treatment, cost $148,530. Therefore, the total cost was $582,573. Approximately 47% of the cost of referrals and initial treatment were due to employee lost productivity. Total cost in the hypothetical cohort was $1,067,948 under the assumptions that all women received screening outside of the workplace, and that the same number of malignancies were detected at the same stage as in the workplace program. These findings indicate referrals resulting in detection of benign disease or no disease accounted for a substantial proportion of the total cost of the program. In addition, employee lost productivity accounted for almost 50%of the cost of all referrals.

Original languageEnglish (US)
Pages (from-to)523-529
Number of pages7
JournalAAOHN Journal
Volume46
Issue number11
StatePublished - Nov 1998

Fingerprint

Early Detection of Cancer
Workplace
Breast Neoplasms
Costs and Cost Analysis
Referral and Consultation
Breast
Neoplasms
Cost of Illness
Insurance Benefits
Occupational Health
Health Care Costs
Therapeutics
Physicians

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Schrammel, P., Griffiths, R. I., & Griffiths, C. B. (1998). A workplace breast cancer screening program: Costs and components. AAOHN Journal, 46(11), 523-529.

A workplace breast cancer screening program : Costs and components. / Schrammel, Peggy; Griffiths, Robert I.; Griffiths, Claudia B.

In: AAOHN Journal, Vol. 46, No. 11, 11.1998, p. 523-529.

Research output: Contribution to journalArticle

Schrammel, P, Griffiths, RI & Griffiths, CB 1998, 'A workplace breast cancer screening program: Costs and components', AAOHN Journal, vol. 46, no. 11, pp. 523-529.
Schrammel P, Griffiths RI, Griffiths CB. A workplace breast cancer screening program: Costs and components. AAOHN Journal. 1998 Nov;46(11):523-529.
Schrammel, Peggy ; Griffiths, Robert I. ; Griffiths, Claudia B. / A workplace breast cancer screening program : Costs and components. In: AAOHN Journal. 1998 ; Vol. 46, No. 11. pp. 523-529.
@article{bcd979528f9e4bca94bf45b0f55f79fe,
title = "A workplace breast cancer screening program: Costs and components",
abstract = "Screening for breast cancer can result in early detection of malignancies and lives saved. Many employers now offer periodic screening as an employee health benefit, and some have established screening programs in the workplace. This study was performed to identify the employer costs of breast cancer screening in the workplace, referrals for suspicious findings, and initial treatment of malignant disease. Additionally, the costs for these same services, had they been obtained outside of a workplace screening program, were estimated. Data on program components and associated costs for an established employer based breast cancer screening program were obtained. These costs were compared to those among a hypothetical cohort of women not enrolled in the workplace screening program. From 1989 through 1995, 1,416 women participated in the program. Nearly 2,500 screening mammograms and approximately 2,773 clinical breast examinations were performed, resulting in 292 referrals to physicians outside of the program for additional diagnostic procedures and treatment as needed. These referrals resulted in the detection of 12 malignancies: 8 Stage I; 3 Stage II; and 1 Stage III. Mammographic and clinical breast examination screening cost $249,041; referrals resulting in benign disease or no detectable disease cost $185,002; and referrals resulting in malignant disease, followed by initial treatment, cost $148,530. Therefore, the total cost was $582,573. Approximately 47{\%} of the cost of referrals and initial treatment were due to employee lost productivity. Total cost in the hypothetical cohort was $1,067,948 under the assumptions that all women received screening outside of the workplace, and that the same number of malignancies were detected at the same stage as in the workplace program. These findings indicate referrals resulting in detection of benign disease or no disease accounted for a substantial proportion of the total cost of the program. In addition, employee lost productivity accounted for almost 50{\%}of the cost of all referrals.",
author = "Peggy Schrammel and Griffiths, {Robert I.} and Griffiths, {Claudia B.}",
year = "1998",
month = "11",
language = "English (US)",
volume = "46",
pages = "523--529",
journal = "Workplace Health and Safety",
issn = "2165-0799",
publisher = "Slack Incorporated",
number = "11",

}

TY - JOUR

T1 - A workplace breast cancer screening program

T2 - Costs and components

AU - Schrammel, Peggy

AU - Griffiths, Robert I.

AU - Griffiths, Claudia B.

PY - 1998/11

Y1 - 1998/11

N2 - Screening for breast cancer can result in early detection of malignancies and lives saved. Many employers now offer periodic screening as an employee health benefit, and some have established screening programs in the workplace. This study was performed to identify the employer costs of breast cancer screening in the workplace, referrals for suspicious findings, and initial treatment of malignant disease. Additionally, the costs for these same services, had they been obtained outside of a workplace screening program, were estimated. Data on program components and associated costs for an established employer based breast cancer screening program were obtained. These costs were compared to those among a hypothetical cohort of women not enrolled in the workplace screening program. From 1989 through 1995, 1,416 women participated in the program. Nearly 2,500 screening mammograms and approximately 2,773 clinical breast examinations were performed, resulting in 292 referrals to physicians outside of the program for additional diagnostic procedures and treatment as needed. These referrals resulted in the detection of 12 malignancies: 8 Stage I; 3 Stage II; and 1 Stage III. Mammographic and clinical breast examination screening cost $249,041; referrals resulting in benign disease or no detectable disease cost $185,002; and referrals resulting in malignant disease, followed by initial treatment, cost $148,530. Therefore, the total cost was $582,573. Approximately 47% of the cost of referrals and initial treatment were due to employee lost productivity. Total cost in the hypothetical cohort was $1,067,948 under the assumptions that all women received screening outside of the workplace, and that the same number of malignancies were detected at the same stage as in the workplace program. These findings indicate referrals resulting in detection of benign disease or no disease accounted for a substantial proportion of the total cost of the program. In addition, employee lost productivity accounted for almost 50%of the cost of all referrals.

AB - Screening for breast cancer can result in early detection of malignancies and lives saved. Many employers now offer periodic screening as an employee health benefit, and some have established screening programs in the workplace. This study was performed to identify the employer costs of breast cancer screening in the workplace, referrals for suspicious findings, and initial treatment of malignant disease. Additionally, the costs for these same services, had they been obtained outside of a workplace screening program, were estimated. Data on program components and associated costs for an established employer based breast cancer screening program were obtained. These costs were compared to those among a hypothetical cohort of women not enrolled in the workplace screening program. From 1989 through 1995, 1,416 women participated in the program. Nearly 2,500 screening mammograms and approximately 2,773 clinical breast examinations were performed, resulting in 292 referrals to physicians outside of the program for additional diagnostic procedures and treatment as needed. These referrals resulted in the detection of 12 malignancies: 8 Stage I; 3 Stage II; and 1 Stage III. Mammographic and clinical breast examination screening cost $249,041; referrals resulting in benign disease or no detectable disease cost $185,002; and referrals resulting in malignant disease, followed by initial treatment, cost $148,530. Therefore, the total cost was $582,573. Approximately 47% of the cost of referrals and initial treatment were due to employee lost productivity. Total cost in the hypothetical cohort was $1,067,948 under the assumptions that all women received screening outside of the workplace, and that the same number of malignancies were detected at the same stage as in the workplace program. These findings indicate referrals resulting in detection of benign disease or no disease accounted for a substantial proportion of the total cost of the program. In addition, employee lost productivity accounted for almost 50%of the cost of all referrals.

UR - http://www.scopus.com/inward/record.url?scp=0031757377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031757377&partnerID=8YFLogxK

M3 - Article

C2 - 9934000

AN - SCOPUS:0031757377

VL - 46

SP - 523

EP - 529

JO - Workplace Health and Safety

JF - Workplace Health and Safety

SN - 2165-0799

IS - 11

ER -